Eighty-seven percent of Hodgkin lymphoma patients responded to a Bristol-Myers Squibb drug that helps the immune system fight the blood cancer, according to data from a small, early stage trial released on Saturday. The study of Bristol-Myers' immunotherapy drug nivolumab involved 23 patients whose lymphoma had progressed after numerous prior treatments, including chemotherapy, stem cell transplants and the Seattle Genetics drug Adcetris.
http://ift.tt/1yB26bq
http://ift.tt/1yB26bq
No comments:
Post a Comment